Prashanth Gopalakrishna Selected Research

Janus Kinases

3/2015	A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.
1/2015	The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Prashanth Gopalakrishna Research Topics

Disease

9	Primary Myelofibrosis (Myelosclerosis) 01/2017 - 01/2015
4	Anemia 01/2017 - 01/2015
4	Splenomegaly 09/2015 - 01/2015
1	Fatigue 01/2019
1	Nausea 01/2019
1	Ovarian Epithelial Carcinoma 01/2019
1	Alopecia (Baldness) 01/2019
1	Diarrhea 01/2019
1	Exanthema (Rash) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Neutropenia 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Vomiting 01/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 07/2013
1	Breast Neoplasms (Breast Cancer) 07/2013

Drug/Important Bio-Agent (IBA)

9	ruxolitinibIBA 01/2017 - 01/2015
2	Janus Kinase 1IBA 09/2015 - 07/2015
2	Janus KinasesIBA 03/2015 - 01/2015
1	acivicin (AT 125)IBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	afuresertibIBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	PlatinumIBA 01/2019
1	Carboplatin (JM8)FDA LinkGeneric 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	nilotinib FDA Link 05/2018
1	Hemoglobins (Hemoglobin)IBA 10/2016
1	Janus Kinase InhibitorsIBA 07/2015
1	HematinicsIBA 01/2015
1	ixabepilone (BMS 247550)FDA Link 07/2013
1	TubulinIBA 07/2013
1	eribulin FDA Link 07/2013

Therapy/Procedure

3	Therapeutics 09/2015 - 01/2015